Components of equity [axis] Ordinary shares [member] Share premium [member] Capital reserve [member] Retained earnings [member] Types of contracts [axis] Securities purchase agreement [member] Pre-funded warrants [Member] Warrants [member] Types of antidilutive instruments [axis] Levels of fair value hierarchy [axis] Level 2 of fair value hierarchy [member] Level 3 of fair value hierarchy [member] Non-adjusting events after reporting period [axis] Nonadjusting event [member] Healthcare AI regulatory sandbox program [member] Categories of related parties [axis] Israel innovation authority [member] Smartscan AI program [member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of financial position [abstract] Assets CURRENT ASSETS Cash and cash equivalents Short-term bank deposits Restricted deposits Trade receivables Other receivables Inventory - current portion Total current assets NON-CURRENT ASSETS Inventory - non-current portion Right-of-use assets Property and equipment, net Total non-current assets Total assets Liabilities and equity CURRENT LIABILITIES Trade payables Warrants Other payables and accruals Contract liabilities Share-based compensation liability Current maturities of liability for royalties to the Israel Innovation Authority Current maturities of lease liabilities Total current liabilities NON-CURRENT LIABILITIES Liability for royalties to the Israel Innovation Authority, net of current maturities Lease liabilities, net of current maturities Total non-current liabilities Total liabilities EQUITY Ordinary shares Share premium Capital reserve Accumulated deficit Total equity Total liabilities and equity Profit or loss [abstract] Revenues Cost of revenues Total revenues Research and development expenses, net Sales and marketing expenses General and administrative expenses Operating loss Financial expenses Financial income Financial expenses (income), net Loss before income tax Provision (benefit) for income tax Net loss and comprehensive loss Loss per ordinary share - basic Loss per ordinary share - diluted Weighted average ordinary shares outstanding - basic Weighted average ordinary shares outstanding - diluted Condensed Consolidated Interim Statements Of Comprehensive Loss Unaudited Prefunded warrants shares Statement of changes in equity [table] IfrsStatementLineItems [Line Items] Balance Net loss and comprehensive loss for the year Share-based compensation Exercise of options Expiration of options Balance Statement of cash flows [abstract] Net cash used in operating activities (see appendix) Cash Flows from Investing Activities Purchase of property and equipment Proceeds from short-term deposits Interest received Net cash provided by investing activities, net Cash Flows from Financing Activities Proceeds from private placement Transaction costs related to private placement Exercise of options Payment to the Israel Innovation Authority Receipt of grants from Israel Innovation Authority Principal portion of lease payments Interest portion of lease payments Net cash provided by (used in) financing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of the year Exchange differences on cash and cash equivalents Cash and cash equivalents at end of the year Net loss Adjustments for: Depreciation and amortization Share-based compensation Financial expenses (income) Exchange differences Adjustments for profit loss Changes in operating asset and liability items: Decrease in trade receivables Increase in other receivables Increase (decrease) in inventory Increase (decrease) in trade payables Decrease in other payables and accruals Increase (decrease) in contract liabilities Increase in liability of share-based compensation Changes in operating asset and liability items, net Net cash used in operating activities Supplemental information on non-cash transactions: Changes in right-of-use asset and lease liabilities Changes in share-based compensation liability General Information GENERAL INFORMATION Notes and other explanatory information [abstract] BASIS OF PREPARATION OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS SIGNIFICANT ACCOUNTING POLICIES FINANCINGS FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT COMMITMENTS AND CONTINGENT LIABILITIES Disclosure of events after reporting period [text block] SUBSEQUENT EVENTS Basis of presentation of the financial statements Convenience translation into U.S. dollars Estimates and judgments SCHEDULE OF FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT SCHEDULE OF CHANGES IN THE FINANCIAL INSTRUMENTS Exchange rate US to NIS Disclosure of disaggregation of revenue from contracts with customers [table] Number of shares issued Par value per share Gross proceeds from offering Commissions and other offering expenses Exercise price Financial expenses Deferred loss Warrants contractual life Amount released to financial expenses Transaction costs not paid Disclosure of fair value measurement of assets [table]  Warrants Balance as of January 1 Initial recognition of financial liability Deferred day 1 loss Change in fair value of warrants Release of day 1 loss Balance as of June 30 Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [table] Share price Strike price Volatility rate Risk-free interest rate Warrants expected life Disclosure of non-adjusting events after reporting period [table] Name of acquiree Total consideration for purchase Project value Grant approved amount Restricted deposits. Sharebased compensation liability. Prefunded warrants. Increase decrease through expiration of options. Disclosure of basis of preparation of financial statement explanatory. Disclosure of accounting policy for estimates and judgements explanatory. Interest portion of lease payments. Payment to israel innovation authority. Changes in operating asset and liability. Increase decrease changes in operating asset and liability items net. Supplemental disclosure of noncash investing activities [Abstract] Changes in right of use asset and lease liabilities. Changes in sharebased compensation liability. Weighted average remaining contractual life of outstanding warrants. Nonadjusting event [member] Pre-funded warrants [Member] Israel innovation authority [member] Initial recognition of financial liability. Disclosure of general information about financial statement explanatory. Change in fair value of warrants. Deferred loss. Release loss. Current royalties liabilities. Noncurrent royalties liabilities. Securities purchase agreement [member] Share issue related cost unpaid. Healthcare AI regulatory sandbox program [member] Smartscan AI program [member] Warrants share price. Warrants exercise price. Description of expected volatility warrants granted. Description of risk-free interest rate warrants granted. Warrants expected life. Current assets Non-current assets Assets [Default Label] Current liabilities Non-current liabilities Liabilities Equity Equity and liabilities Gross profit Operating expense excluding cost of sales Finance income Finance income (expenses) from reinsurance contracts held recognised in profit or loss Profit (loss) before tax Purchase of property, plant and equipment, classified as investing activities Cash flows from (used in) investing activities Payments for share issue costs Proceeds from exercise of options PaymentToIsraelInnovationAuthority Payments of lease liabilities, classified as financing activities InterestPortionOfLeasePayments Cash flows from (used in) financing activities Increase (decrease) in cash and cash equivalents after effect of exchange rate changes Adjustments for share-based payments Adjustments for finance income (cost) Gains (losses) on exchange differences on translation of foreign operations, net of tax Adjustments to reconcile profit (loss) IncreaseDecreaseChangesInOperatingAssetAndLiabilityItemsNet Finance costs Fair value of financial instrument on discontinuation of measurement at fair value through profit or loss because credit derivative is used to manage credit risk, assets ReleaseLoss